<DOC>
	<DOCNO>NCT02283060</DOCNO>
	<brief_summary>Atripla Stribild two FDA-Approved one pill day combination antiretroviral medication give treatment HIV . Both drug reasonably well tolerate . However , efavirenz , component Atripla , know cause `` mental '' side effect . This proposal aim ass whether switch Atripla Stribild 12 week associate reversal sleep cognitive disturbance . Demonstrating change upon withdrawal drug substitution drug regimen know impact sleep cognition may represent best option determine whether use efavirenz associate effect sleep cognition beyond immediate period follow initiation drug .</brief_summary>
	<brief_title>Sleep Cognition After Atripla Stribild Switch</brief_title>
	<detailed_description>Atripla ( efavirenz/emtricitabine/tenofovir disoproxil fumarate ) Stribild ( elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat ) 2 FDA-approved 'one pill day ' combination antiretroviral medication give treatment HIV . Both common nucleoside reverse transcriptase inhibitor ( NRTI ) backbone tenofovir ( TDF ) emtricitabine ( FTC ) , differ 3rd medication contain pill . Atripla contain non-nucleoside reverse transcriptase ( NNRTI ) drug efavirenz ( EFV ) Stribild ( elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat ) contain integrase inhibitor elvitegravir drug cobicistat inactive HIV design simply boost level elvitegravir . Both drug reasonable well tolerate . However , efavirenz know cause 'mental ' side-effects . It known initial use EFV associate central nervous system ( CNS ) toxicity . The symptoms toxicity include daytime sleepiness , alternatively inability sleep , well vivid dream include nightmare . The majority symptom believe resolve within week ; however controversy whether residual problem persist long term basis . Furthermore report long time cognitive dysfunction associate use efavirenz . Whether related sleep disturbance clear . Studies assess impact primarily involve assessment sleep cognitive function antiretroviral ( ART ) -naïve subject initiate first time ART include EFV . Such study however confound 'return health ' phenomena HIV per se know cause sleep cognitive deficit . There controversy regard whether use efavirenz lead long term disturbance sleep cognition . HIV per se cause sleep cognitive deficits6 study try assess problem antiretroviral-naïve subject 's pre- post- initiation efavirenz-based regimen may confound 'return health ' phenomenon . This proposal aim ass whether switch efavirenz/emtricitabine/tenofovir disoproxil fumarate elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat associate reversal sleep cognitive disturbance . Demonstrating change upon withdrawal drug substitution drug regimen know impact sleep cognition may represent best option determine whether use EFV associate effect sleep cognition beyond immediate period follow initiation drug .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>HIV infect Age 18 65 year On stable efavirenz/emtricitabine/tenofovir disoproxil fumarate regimen &gt; 12 month Documented plasma HIV RNA &lt; 50 copies/ml within 3 month entry Ability willingness provide write informed consent Receipt antiretroviral drug addition efavirenz/emtricitabine/tenofovir disoproxil fumarate within 6 month study entry Any document plasma HIV RNA &gt; 100 copies/ml within past 6 month prior study entry Chronic hepatitis B assess positive hepatitis B surface antigen [ HBsAg ] Chronic hepatitis C assess positive hepatitis C antibody [ HCVab ] , except proof viral clearance normal liver function test Other chronic disease uncontrolled likely interfere study result Acute illness within 2 week entry Previously document history OSA ( obstructive sleep apnea ) Moderate high risk OSA define BMI ( Body mass index ) &gt; 30 plus two following : habitual snoring , gasping/choking , observe apnea sleeping , neck circumference &gt; 17 inch Severe depression base BDI2 ( Beck Depression Inventory II ) Chronic daily receipt medication associate potential sleep interference ( i.e . psychoactive drug , steroid , decongestant , beta blocker ) Any immunomodulator , HIV vaccine , vaccine , investigational therapy within 30 day study entry . Anticipated need medication contraindicate per Stribild package insert Any known contraindication use Stribild ( elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat ) Creatinine clearance ( Cockcroft Gault ) &lt; 70 ml/min The following lab value : 1 . Hemoglobin &lt; 9.0 2 . Absolute neutrophil count &lt; 500/μL 3 . Platelet count &lt; 40,000/μL 4 . AST ( SGOT ) ALT ( SGPT ) &gt; 5x ULN Active recent past history ( within past 5 year ) illicit substance alcohol use abuse , judgment Investigator , interfere patient 's ability comply protocol requirement Pregnancy breastfeeding , intent become pregnant course study breastfeed Patients , , opinion Investigator , unable comply dose schedule protocol evaluation study may advisable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Atripla</keyword>
	<keyword>Stribild</keyword>
	<keyword>HIV</keyword>
	<keyword>Sleep architecture</keyword>
	<keyword>Neuropsychological performance</keyword>
</DOC>